J. Baars

J. Baars, J. Beijnen, A. Huitema, 2012, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

The pharmacokinetics of ¹³¹I-rituximab in a patient with CD20 positive non-Hodgkin Lymphoma: evaluation of the effect of radioiodination on the biological properties of rituximab.

J. Baars, J. Beijnen, A. Huitema, 2011, Human antibodies.

High-dose carboplatin, thiotepa and cyclophosphamide (CTC) with peripheral blood stem cell support in the adjuvant therapy of high-risk breast cancer: a practical approach.

S. Rodenhuis, J. Baars, D. Richel, 1995, British Journal of Cancer.

Interleukin-2 toxicity: mechanisms and management

J. Baars, 1993 .

Interleukin‐2 induces activation of coagulation and fibrinolysis: resemblance to the changes seen during experimental endotoxaemia

J. Baars, J. Wagstaff, C. Hack, 1992, British journal of haematology.

The activation of polymorphonuclear neutrophils and the complement system during immunotherapy with recombinant interleukin-2.

J. Baars, C. Hack, L. Thijs, 1992, British Journal of Cancer.

Treatment of leptomeningeal carcinomatosis with continuous intraventricular infusion of recombinant interleukin-2.

J. Baars, C. Polman, J. Heimans, 1991, Surgical neurology.

Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple myeloma: a prospective randomized phase 3 study.

J. Baars, P. Sonneveld, E. Vellenga, 2002, Blood.

Feasibility and toxicity study of a high-dose chemotherapy regimen for autotransplantation incorporating carboplatin, cyclophosphamide and thiotepa.

S. Rodenhuis, J. Baars, D. Richel, 1992, Annals of oncology : official journal of the European Society for Medical Oncology.

Feasibility of multiple courses of high-dose cyclophosphamide, thiotepa, and carboplatin for breast cancer or germ cell cancer.

S. Rodenhuis, J. Baars, J. Schornagel, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

W. Stevens, J. Baars, M. J. van den Bent, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

Treatment of secondary central nervous system lymphoma with intrathecal rituximab, high‐dose methotrexate, and R‐DHAP followed by autologous stem cell transplantation: results of the HOVON 80 phase 2 study

M. Kersten, J. Baars, P. Lugtenburg, 2017, Hematological oncology.

Treatmentt of relapsed B-cell non-Hodgkin's lymphomaa with a combination of chimeric anti-CD200 monoclonal antibodies (rituximab) and G-CSF:: final report on safety and efficacy

J. Baars, A. Grillo-López, V. Oers, 2007 .

Acute painful lumbosacral paresthesia after intrathecal rituximab

J. Baars, M. J. van den Bent, J. Doorduijn, 2011, Journal of Neurology.

Poor outcomes of chronic active Epstein-Barr virus infection and hemophagocytic lymphohistiocytosis in non-Japanese adult patients.

D. de Jong, J. Baars, A. Kater, 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Lobular panniculitis after subcutaneous administration of interleukin-2 (IL-2), and its exacerbation during intravenous therapy with IL-2.

J. Baars, J. Wagstaff, H. Pinedo, 1992, British Journal of Cancer.

Chemotherapy as primary treatment for brain metastases from breast cancer: analysis of 115 one-year survivors

J. Baars, S. Linn, H. Tinteren, 2012, Journal of Cancer Research and Clinical Oncology.

Impact of hyperglycemia on the efficacy of chemotherapy-A systematic review of preclinical studies.

J. Baars, J. Hoekstra, D. L. van der Velden, 2017, Critical reviews in oncology/hematology.

Application of a monoclonal antibody against a neoepitope on activated C4 in an ELISA for the quantification of complement activation via the classical pathway.

J. Baars, C. Hack, G. Wolbink, 1993, Journal of immunological methods.

Long-term risk of cardiovascular disease after treatment for aggressive non-Hodgkin lymphoma.

J. Baars, M. van Glabbeke, S. le Cessie, 2006, Blood.

Relative risk of cardiovascular disease after treatment for aggressive non-Hodgkin's lymphoma

J. Baars, S. Cessie, E. Noordijk, 2005 .

REVIEW OF CARBOPLATIN-BASED HIGH-DOSE CHEMOTHERAPY COMBINATIONS IN THE AUTOTRANSPLANT SETTING

S. Rodenhuis, J. Baars, J. Schornagel, 1996 .

Cerebrovascular events during nilotinib treatment.

J. Baars, N. Jager, F. Stuurman, 2014, The Netherlands journal of medicine.

Specific T-cell subsets and accessory cell types are associated with transformation and prognosis of follicular lymphoma: A gene-expression and immunohistochemical study

A. Glas, L. Delahaye, M. Kersten, 2007 .

Outcome of patients with primary central nervous system lymphoma treated outside clinical trials.

A. Hart, M. Kersten, D. de Jong, 2014, Netherlands Journal of Medicine.

Propofol extravasation in a breast cancer patient

J. Baars, J. Schellens, J. Beijnen, 2008, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

Lethal 5-fluorouracil toxicity associated with a novel mutation in the dihydropyrimidine dehydrogenase gene.

J. Baars, A. V. van Kuilenburg, R. Meinsma, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

Myeloablative allogeneic versus autologous stem cell transplantation in adult patients with acute lymphoblastic leukemia in first remission: a prospective sibling donor versus no-donor comparison.

J. Baars, P. Sonneveld, B. van der Holt, 2009, Blood.

Complement activation plays a key role in the side‐effects of rituximab treatment

J. Baars, C. Hack, L. van der Kolk, 2001, British journal of haematology.

Gene-expression and immunohistochemical study of specific T-cell subsets and accessory cell types in the transformation and prognosis of follicular lymphoma.

Philip M Kluin, Leonie Delahaye, Daphne de Jong, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long-term efficacy of the CHVmP/BV regimen used for aggressive non-Hodgkin's lymphoma in three randomised EORTC trials.

J. Baars, M. van Glabbeke, E. Noordijk, 2004, European journal of cancer.

Randomised trial of high-dose chemotherapy and haemopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph-node involvement

J. Peterse, S. Rodenhuis, J. Baars, 1998, The Lancet.

Rituximab in patients with primary CNS lymphoma (HOVON 105/ALLG NHL 24): a randomised, open-label, phase 3 intergroup study.

W. Stevens, D. de Jong, J. Baars, 2019, The Lancet. Oncology.

High dose chemotherapy in breast cancer reviewed

S. Rodenhuis, J. Baars, J. Schornagel, 1995 .

Impact of involved field radiotherapy in partial response after doxorubicin-based chemotherapy for advanced aggressive non-Hodgkin's lymphoma.

J. Baars, M. van Glabbeke, E. Noordijk, 2006, International journal of radiation oncology, biology, physics.

Risk of second cancer after treatment of aggressive non-Hodgkin's lymphoma; an EORTC cohort study.

J. Baars, M. van Glabbeke, E. Noordijk, 2006, Haematologica.

Treatment of sporadic Burkitt lymphoma in adults, a retrospective comparison of four treatment regimens

M. Kersten, W. Stevens, D. de Jong, 2017, Annals of Hematology.

Quality of life after successful treatment of early-stage Hodgkin's lymphoma: 10-year follow-up of the EORTC-GELA H8 randomised controlled trial.

M. Kersten, A. Hagenbeek, G. Salles, 2009, The Lancet. Oncology.

Hemolytic uremic syndrome after high dose chemotherapy with autologous stem cell support

S. Rodenhuis, J. Baars, H. V. D. Lelie, 1995, Cancer.

prospective sibling donor versus no-donor comparison adult patients with acute lymphoblastic leukemia in first remission: a Myeloablative allogeneic versus autologous stem cell transplantation in

J. Baars, P. Sonneveld, G. Ossenkoppele, 2013 .

Phase I study on the sequential administration of recombinant human interferon-gamma and recombinant human interleukin-2 in patients with metastatic solid tumors.

J. Baars, J. Wagstaff, J. Vermorken, 1991, Journal of the National Cancer Institute.

Determination of capillary leakage due to recombinant interleukin-2 by means of noninvasive conductivity measurements

J. Baars, C. G. Olthof, A. Donker, 2004, European Journal of Applied Physiology and Occupational Physiology.

Angioneurotic oedema and urticaria during therapy with interleukin-2 (IL-2).

J. Baars, J. Wagstaff, C. Hack, 1992, Annals of oncology : official journal of the European Society for Medical Oncology.

Treatment of relapsed B-cell non-Hodgkin's lymphoma with a combination of chimeric anti-CD20 monoclonal antibodies (rituximab) and G-CSF: final report on safety and efficacy

J. Baars, M. V. Oers, A. Grillo‐López, 2003, Leukemia.

Dose intensity of chemotherapy in patients with relapsed Hodgkin's lymphoma.

V. Diehl, J. Raemaekers, N. Schmitz, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Late non-neoplastic events in patients with aggressive non-Hodgkin's lymphoma in four randomized European Organisation for Research and Treatment of Cancer trials.

J. Raemaekers, J. Baars, M. van Glabbeke, 2005, Clinical lymphoma & myeloma.

The toxicity of radiotherapy following high-dose chemotherapy with peripheral blood stem cell support in high-risk breast cancer: a preliminary analysis.

S. Rodenhuis, J. Baars, D. Richel, 1996, European journal of cancer.

The release of interleukin-8 during intravenous bolus treatment with interleukin-2.

J. Baars, J. Wagstaff, C. Hack, 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II study of interferon-gamma and interleukin-2: tachyphylaxis of toxicity to the liver during increasing immune enhancement.

J. Baars, J. Wagstaff, H. Pinedo, 1993, Journal of the National Cancer Institute.

A pilot study to evaluate the effects of C1 esterase inhibitor on the toxicity of high-dose interleukin 2.

J. Baars, C. Hack, L. Thijs, 1994, British Journal of Cancer.

Neurocognitive function of lymphoma patients after treatment with chemotherapy

J. Baars, H. Wouters, S. Schagen, 2016, Acta oncologica.

Efficacy of up-front 5-fluorouracil-epidoxorubicin-cyclophosphamide (FEC) chemotherapy with an increased dose of epidoxorubicin in high-risk breast cancer patients.

J. Peterse, S. Rodenhuis, J. Baars, 1996, British Journal of Cancer.

NEURO/MEDICAL ONCOLOGY

Scott N. Hwang, Katrina H. Smith, Susan M. Chang, 2013 .

Three spectroscopic techniques evaluated as a tool to study the effects of iodination of monoclonal antibodies, exemplified by rituximab.

J. Baars, C. Damen, J. Beijnen, 2011, Journal of pharmaceutical and biomedical analysis.

M. Kersten, J. Baars, O. Visser, 2017, Journal of science and medicine in sport.

Effect of Rituximab in Primary Central Nervous System Lymphoma - results of the Randomized Phase III HOVON 105/ALLG NHL 24 Study

W. Stevens, J. Baars, D. Jong, 2017 .

Risk of second cancer after treatment of aggressive non-Hodgkin's lymphoma; an EORTC cohort study.

J. Baars, E. Noordijk, H. Kluin-Nelemans, 2006, Haematologica.

Dose intensity of chemotherapy in patients with relapsed Hodgkin's lymphoma.

V. Diehl, J. Raemaekers, N. Schmitz, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The pharmacokinetics of 131I-rituximab in a patient with CD20 positive Non-Hodgkin Lymphoma: Evaluation of the effect of radioiodination on the biological properties of rituximab

J. Baars, J. Beijnen, A. Huitema, 2011 .

At home management of aplastic phase following high-dose chemotherapy with stem-cell rescue for hematological and non-hematological malignancies.

S. Rodenhuis, J. Baars, J. Schornagel, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.